Tenaya Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on the stock and has a $5.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight the promising potential of Tenaya Therapeutics’ TN-201 gene therapy. The interim data from the MyClimb study, presented at the European Society of Cardiology 2025, underscores the significant unmet need in pediatric hypertrophic cardiomyopathy (HCM) and the potential of TN-201 to address this gap. The study, which is the largest of its kind, involves over 200 participants and provides valuable insights into the disease burden and progression in young patients, thereby informing future clinical trial designs.
Key findings from the study reveal distinct genetic risk profiles among participants, with severe outcomes noted in certain genetic groups, such as the homozygous and compound heterozygous groups. These insights, along with the identification of left ventricular mass index (LVMI) as a potential surrogate marker for early effectiveness, support the advancement of TN-201 into clinical trials. The compelling data and the high unmet need in this patient population contribute to Pantginis’s optimistic outlook and Buy rating for Tenaya Therapeutics.
In another report released on August 29, LifeSci Capital also maintained a Buy rating on the stock with a $3.00 price target.